ARCH Venture Management, LLC Diversified Active

CIK: 0001274403 · Show all filings

Period: Q4 2022 (← Previous) (Next →)

Filing Date: Feb 14, 2023

Total Value ($000): $390,418 (100.0% shares, 0.0% debt)

Holdings (8)

DNLI DENALI THERAPEUTICS, INC. 26.1%

Value ($000) $102,028 Shares 3,668,749 Est. Cost $26.20 Unrealized +13.6%

— KARUNA THERAPEUTICS, INC. 25.8%

Value ($000) $100,779 Shares 512,872 Est. Cost $131.00 Unrealized —

— EQRX, INC. 22.9%

Value ($000) $89,385 Shares 36,335,375 Est. Cost $6.82 Unrealized —

ERAS ERASCA, INC. 12.2%

Value ($000) $47,649 Shares 11,055,554 Est. Cost $17.12 Unrealized -60.4%

— VERVE THERAPEUTICS, INC. 10.0%

Value ($000) $38,870 Shares 2,008,809 Est. Cost $36.87 Unrealized —

— SINGULAR GENOMICS SYSTEMS, INC. 2.0%

Value ($000) $7,636 Shares 3,798,926 Est. Cost $11.56 Unrealized —

— UNITY BIOTECHNOLOGY, INC. 0.7%

Value ($000) $2,753 Shares 1,004,817 Est. Cost $0.40 Unrealized —

— METACRINE, INC. 0.3%

Value ($000) $1,317 Shares 2,940,503 Est. Cost $0.61 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
DNLI	DENALI THERAPEUTICS, INC.	3,668,749	$102,028	26.1%	$26.20	+13.6%	COM	24823R105
—	KARUNA THERAPEUTICS, INC.	512,872	$100,779	25.8%	$131.00	—	COM	48576A100
—	EQRX, INC.	36,335,375	$89,385	22.9%	$6.82	—	COM	26886C107
ERAS	ERASCA, INC.	11,055,554	$47,649	12.2%	$17.12	-60.4%	COM	29479A108
—	VERVE THERAPEUTICS, INC.	2,008,809	$38,870	10.0%	$36.87	—	COM	92539P101
—	SINGULAR GENOMICS SYSTEMS, INC.	3,798,926	$7,636	2.0%	$11.56	—	COM	82933R100
—	UNITY BIOTECHNOLOGY, INC.	1,004,817	$2,753	0.7%	$0.40	—	COM	91381U200
—	METACRINE, INC.	2,940,503	$1,317	0.3%	$0.61	—	COM	59101E103